Chinook Therapeutics, Inc.
108 articles about Chinook Therapeutics, Inc.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - Apr 08, 2021
4/8/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming virtual investor conferences
-
Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4/7/2021
- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the full year ended December 31, 2020.
-
Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
4/7/2021
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient has been dosed in the AFFINITY Study, a phase 2 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor
-
Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
4/5/2021
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a transaction with Van Herk Investments, a leading European life science investor, to create and fund a new company called Sairopa
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2021
4/1/2021
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 83,599 shares of common stock with a grant date of March 31, 2021 for two new employees.
-
Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress
3/30/2021
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at the ISN World Congress of Nephrology 2021 from April 15 – 19, 2021 and the 58th ERA-EDTA Congress from June 5 – 8, 2021.
-
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
3/16/2021
Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - Mar 02, 2021
3/2/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences
-
Evotec and Chinook Therapeutics Enter Into Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
3/1/2021
Evotec SE and Chinook Therapeutics, Inc. announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases.
-
Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
3/1/2021
Collaboration will Leverage Access to the NURTuRE Patient Biobank and Evotec’s PanHunter Multi-Omics Platform to Characterize Molecular Drivers, Identify and Validate Novel Targets and Drive Patient Stratification Strategies in Kidney Disease Collaboration Will Focus on Polycystic Kidney Disease (PKD), Lupus Nephritis, IgA Nephropathy and Other Primary Glomerular Diseases
-
Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit
2/23/2021
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine, will present on behalf of Chinook at the 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit.
-
Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2/17/2021
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the 10 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 10:00 am ET.
-
Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria
2/2/2021
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for CHK-336,
-
When Chinook Therapeutics looks at 2021, it foresees a host of clinical trials that will bring precision medicine to the kidney disease space.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - Jan 04, 2021
1/4/2021
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in presentations at the following upcoming virtual investor conferences:
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/30/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock
-
Chinook Therapeutics to Present at Upcoming Investor Conferences
11/18/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences
-
Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer
11/10/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Eric Bjerkholt as Chief Financial Officer (CFO).
-
Chinook Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
11/5/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced third quarter 2020 financial results and provided a business update.
-
Chinook Therapeutics Presents Data Across Kidney Disease Pipeline During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined
10/22/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced three poster presentations and one oral presentation at ASN’s Kidney Week 2020 Reimagined.